sur Isomorphic Labs
Isomorphic Labs Secures $5 Billion in Series C Funding
Isomorphic Labs, an AI-focused company in drug development, has announced the completion of a $5 billion Series C funding round. The round was co-led by Greenoaks and Sequoia Capital, with significant contributions from Andreessen Horowitz and Alphabet. Existing investors, such as Thrive Capital and Temasek, also participated.
The funding will enhance the development of Isomorphic's drug design engine, IsoDDE, which employs AI models to explore chemical spaces and refine drug design. IsoDDE aims to transform biological systems predictions, supporting advances across a pipeline of therapeutic candidates.
The capital will drive expansion into new biological models and support clinical trial infrastructure. CEO Sir Demis Hassabis emphasized the potential for AI in understanding biology at a molecular level and speeding up drug discovery.
Investors express confidence in Isomorphic's transformative approach to medicine, noting its capacity for breakthroughs in AI-led drug discovery.
R. H.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Isomorphic Labs